北陆药业跌2.03%，成交额1.15亿元，主力资金净流出1513.50万元

Group 1 - The core viewpoint of the news is that Beilu Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.03% and a year-to-date increase of 41.46% [1] - As of November 18, the stock price is reported at 8.70 yuan per share, with a total market capitalization of 4.897 billion yuan [1] - The company has seen a net outflow of 15.135 million yuan in principal funds, with significant selling pressure from large orders [1] Group 2 - Beilu Pharmaceutical operates in the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations [2] - For the period from January to September 2025, the company achieved operating revenue of 873 million yuan, representing a year-on-year growth of 19.59%, and a net profit attributable to shareholders of 44.177 million yuan, up 81.10% year-on-year [2] - The company's main business revenue composition includes contrast agents (63.33%), traditional Chinese medicine (22.09%), and hypoglycemic drugs (12.75%) [1] Group 3 - Since its A-share listing, Beilu Pharmaceutical has distributed a total of 369 million yuan in dividends, with 59.0327 million yuan distributed over the past three years [3]